Hepatitis B surface antigen quantification as a current-day paradox: Obtaining the gold in the face of diminishing returns # †
Open Access
- 27 March 2009
- journal article
- editorial
- Published by Wolters Kluwer Health in Hepatology
- Vol. 49 (4) , 1063-1065
- https://doi.org/10.1002/hep.22932
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Benefits and risks of interferon therapy for hepatitis B #Hepatology, 2009
- Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B # †Hepatology, 2009
- Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients #Hepatology, 2009
- Sustained HBeAg and HBsAg Loss After Long-term Follow-up of HBeAg-Positive Patients Treated With Peginterferon α-2bGastroenterology, 2008
- Predicting response to peginterferon -2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis BGut, 2007
- HBsAg seroclearance in asymptomatic carriers of high endemic areasHepatology, 2007
- Chronic hepatitis BHepatology, 2007
- Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis BNew England Journal of Medicine, 2004
- Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy1 ☆Gastroenterology, 2004
- Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter studyJournal of Hepatology, 1994